These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35733407)

  • 1. Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis.
    Ladefoged BT; Dybro A; Dahl Pedersen AL; Rasmussen TB; Vase HØ; Clemmensen TS; Gillmore J; Poulsen SH
    ESC Heart Fail; 2022 Oct; 9(5):2978-2987. PubMed ID: 35733407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy.
    Sanne Bøjet L; Bertil L; Anders Lehmann Dahl P; Jens Kæstel S; Tor Skibsted C; Steen Hvitfeldt P
    Ann Med; 2024 Dec; 56(1):2398735. PubMed ID: 39247984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
    Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and prognostic implications of orthopedic ligament disorders in patients with wild-type transthyretin amyloidosis cardiomyopathy.
    Klarskov VR; Ladefoged BT; Pedersen ALD; Hartig-Andreasen C; Clemmensen TS; Poulsen SH
    J Cardiol; 2023 Aug; 82(2):122-127. PubMed ID: 37141937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
    Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
    Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.
    Mints YY; Doros G; Berk JL; Connors LH; Ruberg FL
    ESC Heart Fail; 2018 Oct; 5(5):772-779. PubMed ID: 29916559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
    Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders.
    López-Sainz Á; de Haro-Del Moral FJ; Dominguez F; Restrepo-Cordoba A; Amor-Salamanca A; Hernandez-Hernandez A; Ruiz-Guerrero L; Krsnik I; Cobo-Marcos M; Castro V; Toquero-Ramos J; Lara-Pezzi E; Fernandez-Lozano I; Alonso-Pulpon L; González-López E; Garcia-Pavia P
    Amyloid; 2019 Sep; 26(3):156-163. PubMed ID: 31210553
    [No Abstract]   [Full Text] [Related]  

  • 9. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score.
    Gioia G; Schrutka L; Jozwiak-Nozdrzykowska J; Kresoja KP; Gunold H; Klingel K; Thiele H; Bonderman D; Lurz P; Rommel KP
    ESC Heart Fail; 2024 Aug; 11(4):2172-2181. PubMed ID: 38613409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.
    Connors LH; Sam F; Skinner M; Salinaro F; Sun F; Ruberg FL; Berk JL; Seldin DC
    Circulation; 2016 Jan; 133(3):282-90. PubMed ID: 26660282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.
    Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
    Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
    ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
    Porcari A; Rossi M; Cappelli F; Canepa M; Musumeci B; Cipriani A; Tini G; Barbati G; Varrà GG; Morelli C; Fumagalli C; Zampieri M; Argirò A; Vianello PF; Sessarego E; Russo D; Sinigiani G; De Michieli L; Di Bella G; Autore C; Perfetto F; Rapezzi C; Sinagra G; Merlo M
    Eur J Heart Fail; 2022 Jul; 24(7):1227-1236. PubMed ID: 35509181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis.
    Kharoubi M; Roche F; Bézard M; Hupin D; Silva S; Oghina S; Chalard C; Zaroui A; Galat A; Guendouz S; Canoui-Poitrine F; Hittinger L; Teiger E; Lefaucheur JP; Damy T
    ESC Heart Fail; 2021 Apr; 8(2):1656-1665. PubMed ID: 33354901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.
    Hanson JLS; Arvanitis M; Koch CM; Berk JL; Ruberg FL; Prokaeva T; Connors LH
    Circ Heart Fail; 2018 Feb; 11(2):e004000. PubMed ID: 29449366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Castaño A; Heitner SB; Masri A; Huda A; Calambur V; Bruno M; Schumacher J; Emir B; Isherwood C; Shah SJ
    J Card Fail; 2024 Jun; 30(6):778-787. PubMed ID: 38065306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.